Ms. Clague has served as Chief Financial Officer of rare disease leader Retrophin since November 2014. Ms. Clague has 30 years of experience as a financial executive, and oversees the company’s accounting, finance, IT and facilities functions. Previously, Ms. Clague served as chief financial officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the vice president, corporate controller and principal accounting officer of Amylin for 10 years, when she also served as the chief financial officer of Amylin's collaboration with Eli Lilly and Company. Ms. Clague currently serves on the board of directors of LRAD Corporation. Ms. Clague is a Certified Public Accountant in the State of California, and received a BS in business administration from Menlo College.